Conference Track

Timing and Choice of First-Line Antiretroviral Therapy

Source: CCO Official Conference Coverage of the 2008 International AIDS Conference

Capsule Summaries

Virologic Suppression Maintained With Switch to Abacavir From Thymidine Analogues in Patients Receiving Effective HAART
Study 903E: 7-Year Follow-up of Patients on Tenofovir, Lamivudine, Efavirenz Demonstrates Durable Virologic Suppression, Increased Limb Fat, No Significant Bone, Renal Toxicities
CASTLE: Differences in Safety Outcomes Among Races Found With Atazanavir/Ritonavir vs Lopinavir/Ritonavir in Treatment-Naive Patients
Persistently Low CD4+ Cell Count Despite Complete Virologic Suppression Associated With Increased Risk of AIDS or Death
Raltegravir Associated With Sustained Viral Suppression Comparable With Efavirenz at Week 96 in Antiretroviral-Naive Patients
Rilpivirine (TMC278) Effective, Well Tolerated in Antiretroviral-Naive Patients Through 96 Weeks
Efavirenz Superior to Lopinavir/Ritonavir in HIV-Infected Patients Presenting With CD4+ Cell Counts < 200 cells/mm³ in Mexico
Earlier Occurrence of Virologic Failure and Adverse Events Found in Patients Receiving Abacavir/Lamivudine vs Tenofovir/Emtricitabine in First-Line Antiretroviral Therapy
Review of 6 Clinical Trials Finds No Evidence of Difference in Virologic Response to Abacavir/Lamivudine by Baseline HIV-1 RNA
Analysis of SMART Data Consistent With D:A:D Finding That Abacavir Is Associated With Increased Risk for Cardiovascular Events
Novel NNRTI IDX899 Shown to Reduce HIV-1 RNA Following 7 Days of Monotherapy in Antiretroviral-Naive Patients
Novel NNRTI RDEA806 Demonstrates Antiviral Activity Without Significant Adverse Events in 7-Day Monotherapy Study
PEARLS/ACTG 5175: First-line HAART Regimen of Didanosine-EC, Emtricitabine, Atazanavir Associated With Increased Risk of Treatment Failure
Heat-Stable Ritonavir Tablet Demonstrates Bioequivalence With Soft-Gel Capsule Formulation in Single-Dose Pharmacokinetics Study
HEAT: Comparable Virologic Suppression, Safety of First-Line Abacavir/Lamivudine vs Tenofovir/Emtricitabine at 96 Weeks

Expert Analysis

Timing and Choice of First-Line Antiretroviral Therapy

Faculty:

Joel E. Gallant, MD, MPH
José Gatell, MD
W. David Hardy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain new findings from prospective and retrospective studies comparing different NRTI backbones in first-line antiretroviral therapy
Discuss new data on the relative efficacy of various antiretroviral agents in first-line therapy
Describe the role of immunologic response to HAART in patient outcomes and the implications for the benefit of early first-line treatment
Cite new results on the safety and efficacy of different boosted PI regimens among racial subgroups

CREDIT INFORMATION

Release Date: October 08, 2008

Expiration Date: October 07, 2009

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.